Found Reviews Metformin
The default first rung. Found's economics improve when members respond here and never escalate, which is the alignment self-insured buyers should be looking for.
Sold as Glucophage · Reviewed September 19, 2026
What “First-line” means here
Prescribed as a first-line option. No lower-cost trial is required before a member can start.
The pairing
How Found handles Metformin
These are the vendor-specific mechanics that determine what this molecule actually costs you and whether members stay on it long enough to benefit.
- Access status
- First-line
- Gating
- Offered first to most eligible members regardless of BMI tier.
- Prescribes directly
- Yes
- Step therapy
- Yes
- Prior authorization
- Yes
- Titration protocol
- Protocolized titration with step therapy through lower-cost agents before branded GLP-1s
- Off-ramp
- Maintenance track with scheduled dose-reduction trials
- Care team
- Physicians, Nurse practitioners, Registered dietitians, Behavioral coaches
Ask Found this
What share of enrolled members are maintained on metformin or another low-cost agent at 12 months without escalating to an incretin?
Watch out
Step therapy is a clinical default, not a contractual commitment. Get the escalation criteria written into the agreement.
The molecule
Metformin in one page
Not a GLP-1, and not a weight-loss drug — but the first rung of nearly every credible step-therapy protocol, and effectively free. How a vendor uses metformin tells you whether its cost discipline is real.
Clinical profile
- Drug class
- Biguanide
- Brand names
- Glucophage — Type 2 diabetes
- Mechanism
- Reduces hepatic glucose production and improves insulin sensitivity. Weight effect is modest and secondary to the glycemic effect.
- Administration
- Oral, daily, usually with an extended-release formulation to improve tolerability.
- Titration
- Gradual escalation over several weeks, primarily to manage gastrointestinal tolerability.
- Typical result
- Modest weight reduction — typically low single digits as a percentage — alongside meaningful glycemic improvement in appropriate patients.
- Generic available
- Yes
Known side effects
- Gastrointestinal effects, substantially reduced by extended-release formulations
- Long-term B12 depletion warranting periodic monitoring
- Lactic acidosis, rare and largely confined to renal impairment
What benefits teams need to know
A useful test of vendor honesty
Every vendor lists metformin. Far fewer can show you what share of their population is maintained on it without escalating. Ask for that number — it separates vendors with a step-therapy protocol from vendors with a step-therapy slide.
It does not compete with GLP-1s on weight
Metformin is not an alternative to incretin therapy for a member who needs substantial reduction. Its role is identifying the members who never needed the expensive drug, not substituting for it in those who do.
Alternatives
Other vendors and Metformin
Same molecule, materially different access rules. The status column is where the cost difference lives.
| Vendor | Access | Score | PMPM |
|---|---|---|---|
| Virta Health Metabolic specialist | First-line | 8.7 | $40–$95 |
| Form Health Full-service clinical | Adjunct | 8.0 | $58–$105 |
| Twin Health Metabolic specialist | First-line | 7.8 | $55–$120 |
| Vida Health Full-service clinical | First-line | 7.5 | $38–$78 |
| Teladoc Health Navigation & orchestration | First-line | 7.4 | $18–$44 |
| 9amHealth Metabolic specialist | First-line | 7.3 | $34–$72 |
Same vendor
Found across the formulary
How this vendor positions each molecule tells you more about its cost discipline than any single review does.
Reached only after a documented trial of lower-cost therapy. Step therapy is written into Found's clinical protocol rather than bolted on by your PBM, which is unusual among prescribing vendors.
Sits at the top of the escalation ladder. Members generally reach it only after both a lower-cost agent and, in many cases, semaglutide have been tried.